Conundrum of the HOPE study: time of taking ramipril may account for lack of relation between blood pressure and outcome
- PMID: 14509993
- PMCID: PMC196432
- DOI: 10.1136/bmj.327.7416.681-c
Conundrum of the HOPE study: time of taking ramipril may account for lack of relation between blood pressure and outcome
Comment in
-
Timing of drug treatment is crucial.BMJ. 2004 Jan 17;328(7432):167. doi: 10.1136/bmj.328.7432.167-a. BMJ. 2004. PMID: 14726362 Free PMC article. No abstract available.
Comment on
-
Use of ramipril in preventing stroke: double blind randomised trial.BMJ. 2002 Mar 23;324(7339):699-702. doi: 10.1136/bmj.324.7339.699. BMJ. 2002. PMID: 11909785 Free PMC article. Clinical Trial.
References
-
- HOPE Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-53. - PubMed
-
- Sleight P, Yusuf S, Pogue J, Psuyuki R, Probstfield J. Blood pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358: 2130-1. - PubMed
-
- Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38: e28-32. - PubMed
-
- Sleight P, Pogue J, Yusef S. Blood pressure and cardiovascular risk in the HOPE study. Author's reply. Lancet 2002;359: 2118. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical